Mirin

ArtNr	HY-19959-200mg
Hersteller	MedChem Express
CAS-Nr.	1198097-97-0
Menge	200 mg
Quantity options	100 mg 10 mM/1 mL 10 mg 200 mg 25 mg 50 mg 5 mg
Kategorie	Food Safety Allergenes Inhibitors & Compound Libraries Small Molecules
Typ	Inhibitors
Specific against	other
Purity	99.63
Citations	[1]Rozier L, et al. The MRN-CtIP pathway is required for metaphase chromosome alignment. Mol Cell. 2013 Mar 28;49(6):1097-107.\|[2]Lee JH, et al. Ataxia telangiectasia-mutated (ATM) kinase activity is regulated by ATP-driven conformational changes in the Mre11/Rad50/Nbs1 (MRN) complex. J Biol Chem. 2013 May 3;288(18):12840-51.\|[3]Garner KM, et al. Corrected structure of Mirin, a small-molecule inhibitor of the Mre11-Rad50-Nbs1 complex. Nat Chem Biol. 2009 Mar;5(3):129-30.\|[4]Aude Dupré, et al. A forward chemical genetic screen reveals an inhibitor of the Mre11-Rad50-Nbs1 complex. Nat Chem Biol. 2008 Feb;4(2):119-25.\|[5]Adel Alblihy, et al. Selective Killing of BRCA2-Deficient Ovarian Cancer Cells via MRE11 Blockade. Int J Mol Sci. 2023 Jun 30;24(13):10966.
Smiles	O=C1N=C(S/C1=C\C2=CC=C(C=C2)O)N
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	1198097-97-0
Versandbedingung	Raumtemperatur
Lieferbar
Manufacturer - Type	Reference compound
Manufacturer - Applications	Cancer-programmed cell death
Manufacturer - Targets	Apoptosis; ATM/ATR
Shipping Temperature	Room Temperature
Storage Conditions	-20°C, 3 years; 4°C, 2 years (Powder)
Molecular Weight	220.25
Product Description	Mirin is a potent Mre11-Rad50-Nbs1 (MRN) complex inhibitor. Mirin prevents MRN-dependent activation of ATM (IC50=12 μM) without affecting ATM protein kinase activity, and it inhibits Mre11-associated exonuclease activity. Mirin abolishes the G2/M checkpoint and homology-dependent repair in mammalian cells. Mirin prevents ATM activation in response to DNA double-strand breaks (DSBs) and blocks homology-directed repair (HDR) in mammalian cells[1][2].
Manufacturer - Research Area	Cancer
Solubility	DMSO: ≥ 31 mg/mL
Manufacturer - Pathway	Apoptosis; Cell Cycle/DNA Damage; PI3K/Akt/mTOR
Clinical information	No Development Reported

Hinweis: Die dargestellten Informationen und Dokumente (Bedienungsanleitung, Produktdatenblatt, Sicherheitsdatenblatt und Analysezertifikat) entsprechen unserem letzten Update und sollten lediglich der Orientierung dienen. Wir übernehmen keine Garantie für die Aktualität. Für spezifische Anforderungen bitten wir Sie, uns eine Anfrage zu stellen.

Alle Produkte sind nur für Forschungszwecke bestimmt. Nicht für den menschlichen, tierärztlichen oder therapeutischen Gebrauch.

Arbeitsanleitung (Data Sheet) anfordern

Produkt-Datenblatt anfordern

HY-19959-200mg-safety-datasheet.pdf